TipRanks
Alnylam Pharmaceuticals (DE:DUL)
XETRA:DUL

Compare Alnylam Pharma (DUL) vs. Competitors

4 Followers

Comparison Results

Name
Price
Market Cap
P/E Ratio
Yearly Gain
Analyst Consensus
Analyst Price Target
Compare
Top Analysts' Price Target
Smart Score
Follow
Alnylam Pharma
€249.30
€30.13B
41.86
-42.11%
18 Buy
3 Hold
0 Sell
Strong Buy
Arrowhead Pharmaceuticals
$88.88
$9.31B
-29.22
96.12%
11 Buy
1 Hold
0 Sell
Strong Buy
BioMarin Pharmaceutical
$66.12
$11.66B
156.47
10.83%
17 Buy
5 Hold
0 Sell
Strong Buy
Ionis Pharmaceuticals
$63.57
$7.40B
-13.17
-28.46%
17 Buy
4 Hold
0 Sell
Strong Buy
Intellia Therapeutics
$13.51
$1.65B
-3.40
-28.90%
6 Buy
4 Hold
2 Sell
Moderate Buy
Crispr Therapeutics AG
$60.90
$5.24B
-11.36
-12.18%
8 Buy
5 Hold
0 Sell
Moderate Buy

Performance Comparison

Ticker
Company Name
Price
Change
% Change
DE:DUL
Alnylam Pharma
222.80
-163.70
-42.35%
ARWR
Arrowhead Pharmaceuticals
66.25
31.76
92.08%
BMRN
BioMarin Pharmaceutical
59.87
5.71
10.54%
IONS
Ionis Pharmaceuticals
45.89
-19.53
-29.85%
NTLA
Intellia Therapeutics
12.03
-5.24
-30.34%
CRSP
Crispr Therapeutics AG
56.00
-8.81
-13.59%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts